What should the optimal target hemoglobin be?

Kidney International, Supplement

Volumn 61, Issue 80, 2002, Pages S39-S43

  López Gómez, Juan M ^a,b   Carrera, Fernando ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b Hospital SAMS   (Portugal)

Author keywords

Anemia; Chronic renal disease; Dialysis; Left ventricular hypertrophy; Renal anemia

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

AGE; ANEMIA; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COGNITION; COMORBIDITY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; EMPLOYMENT; HEALTH CARE QUALITY; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; HYPERACTIVITY; HYPERTENSION; MORBIDITY; MORTALITY; PATIENT CARE; PHYSICAL ACTIVITY; POSTOPERATIVE THROMBOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SEX; SYMPTOM; TREATMENT OUTCOME; VASCULAR ACCESS; BLOOD; CHRONIC DISEASE; KIDNEY DISEASE; REVIEW;

ANEMIA; CHRONIC DISEASE; COGNITION; HEMOGLOBINS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; QUALITY OF LIFE;

EID: 0036098534     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.61.s80.8.x     Document Type: Article

References (49)

1. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin
2. Anaemia in end-stage renal disease: Pathophysiological considerations
3. European best practice guidelines for the management of anemia in patients with chronic renal failure
4. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure
5. Haemodynamic changes and physical performance at comparative levels of haemoglobin after long-term treatment with recombinant erythropoietin
6. Normalization of hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients
7. Normalizing hematocrit in dialysis patients improves brain function
8. Effect of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal disease
9. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
10. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: A prospective study
11. Long-term myocardial effects on correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis
12. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin
13. Long-term cardio-respiratory effects of amelioration of renal anaemia by erythropoietin
14. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy
15. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention
16. Cardiovascular effects of recombinant human erythropoietin in predialysis patients
17. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure
18. Use of erythropoietin before the initiation of dialysis and its impact on mortality
19. The CREATE trial-building the evidence
20. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients
21. Improvement of brain function in hemodialysis patients treated with erythropoietin
22. Cognitive function, mood and P3 latency: Effects of the amelioration of anemia in dialysis patients
23. Effects of rHuEPO on Q-EEG and event-related potentials in chronic renal failure
24. Effect of normalization of hematocrit on brain circulation and metabolism in hemodilaysis patients
25. Working capacity is increased following recombinant human erythropoietin treatment
26. Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin
27. Normalization of hematocrit with recombinant human erythropoietin in chronic hemodialysis patients does not fully improve their exercises abilities
28. Recombinant human erythropoietin in predialysis patients
29. Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients
30. Quality of life in dialysis patients: A Spanish multicentre study
31. Health-related quality of life associated with rHu-EPO therapy for predialysis chronic renal disease patients
32. Controlled study in the improvement of quality of life in elderly hemodialysis patients after correcting ESRD related anemia with erythropoietin
33. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients
34. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin
35. Erythropoietin in chronic renal failure
36. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease
37. Hematocrit level and associated mortality in hemodialysis patients
38. Hematocrit levels and hospitalization risks in hemodialysis patients
39. Erythropoietin for end-stage renal disease
40. The Normal Haematocrit Trial in dialysis patients with cardiac disease: Are we any the less confused about target haemoglobin
41. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%
42. Erythropoietin for anaemia in haemodialysis patients: Results of a maintenance study
43. Practical considerations of recombinant erythropoietin therapy
44. The long-term effects of recombinant human erythropoietin on the cardiovascular system
45. Normalization of hematocrit in hemodialysis patients does not affect silent ischemia
46. Individualizing target haemoglobin concentrations - Tailoring treatment for renal anaemia